Alkermes plc (NASDAQ:ALKS) EVP Craig C. Hopkinson Sells 144,419 Shares

Alkermes plc (NASDAQ:ALKS) EVP Craig C. Hopkinson sold 144,419 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the sale, the executive vice president now owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. This represents a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Alkermes Trading Down 0.3 %

NASDAQ:ALKS opened at $35.89 on Friday. Alkermes plc has a 12 month low of $22.90 and a 12 month high of $36.25. The firm has a market cap of $5.81 billion, a price-to-earnings ratio of 18.41, a P/E/G ratio of 1.83 and a beta of 0.49. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The company’s 50 day moving average is $30.31 and its 200-day moving average is $28.73.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%. Equities analysts anticipate that Alkermes plc will post 2.23 EPS for the current year.

Analysts Set New Price Targets

ALKS has been the subject of several research reports. JPMorgan Chase & Co. decreased their price target on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Mizuho lifted their target price on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and lifted their target price for the company from $25.00 to $36.00 in a research note on Tuesday, November 5th. Cantor Fitzgerald reduced their target price on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Finally, The Goldman Sachs Group lifted their target price on shares of Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.25.

Hedge Funds Weigh In On Alkermes

A number of institutional investors and hedge funds have recently bought and sold shares of ALKS. Venturi Wealth Management LLC bought a new position in Alkermes during the fourth quarter worth $25,000. V Square Quantitative Management LLC bought a new position in Alkermes during the third quarter worth $29,000. EverSource Wealth Advisors LLC increased its position in Alkermes by 106.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company’s stock worth $47,000 after acquiring an additional 842 shares during the period. Blue Trust Inc. increased its holdings in Alkermes by 2,231.5% in the 4th quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock valued at $49,000 after buying an additional 1,629 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in Alkermes by 558.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock valued at $85,000 after buying an additional 2,502 shares during the period. Institutional investors own 95.21% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.